How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
In This Article:
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.
Try again.